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Introduction: In a national, integrated health care system, we sought 
to identify facility-level attributes associated with better quality of 
lung cancer care.
Methods: Adherence to 23 quality indicators across four domains 
(Diagnosis and Staging, Treatment, Supportive Care, End-of-Life 
Care) was assessed through abstraction of electronic records from 
4804 lung cancer patients diagnosed in 2007 at 131 Veterans Health 
Administration facilities. Performance was reported as proportions 
of eligible patients fulfilling adherence criteria. With stratification of 
patients by stage, generalized estimating equations identified facil-
ity-level characteristics associated with performance by domain.
Results: Overall performance was high for the older (mean age 
67.7 years, SD 9.4 years), predominantly male (98%) veterans. 
However, no facility did well on every measure, and range of adher-
ence across facilities was large; 9% of facilities were in the highest 
quartile for one or more domain of care, more than 30% for two, 
and 65% for three. No facility performed consistently well across all 
domains. Less than 1% performed in the lowest quartile for all. Few 
facility-level characteristics were associated with care quality. For 
End-of-Life Care, diagnosis and treatment within the same facility, 
availability of cancer psychiatry/psychology consultation services, 
and availability of both inpatient and outpatient palliative care con-
sultation services were associated with better adherence.
Conclusions: Quality of Veterans Health Administration lung can-
cer care is generally high, though substantial variation exists across 
facilities. With the exception of the salutary impact of palliative 
care consultation services on end-of-life quality of care, observed 
 facility-level characteristics did not consistently predict adherence to 
indicators, suggesting quality may be determined by complex local 
factors that are difficult to measure.
Key Words: Lung cancer, Quality of care, Integrated health care.
(J Thorac Oncol. 2014;9: 447–455)
As the burden of lung cancer and its care continues to rise in society at large, monitoring care quality remains cru-
cial not only to understand the status of care provision at any 
given moment, but also to improve and sustain it over time.1 
Studies of cancer care have shown that, although provid-
ers often form the front line in terms of performance, much 
of the variation seen and potentially modified with regard to 
 guideline-recommended practices occurs at the facility level.2 
A number of organizational characteristics, including aca-
demic affiliation, for-profit status, staffing, and computerized 
order entry, to name a few, have been variously found to be 
associated with performance and outcomes.3–8 A greater under-
standing of these factors and their inter-relationships is critical 
to inform targeted interventions and systems design to support, 
encourage, and maintain better quality of cancer care.8
By linking data from a recent national study to evalu-
ate the quality of lung cancer care in the Veterans Health 
Administration (VHA) with detailed information regarding 
the structure of cancer care delivery across 131 facilities, we 
sought to understand the variation in facility-level perfor-
mance on quality indicators spanning the continuum of care 
from diagnosis to the end of life.
MATERIALS AND METHODS
Study Population
Incident cases of lung cancer diagnosed across 131 
facilities within the VHA during 2007 (N = 7816) were iden-
tified by the Veterans Affairs Central Cancer Registry. If the 
medical record did not have pathological confirmation of the 
diagnosis from the facility that registered the case, the case 
was excluded, as abstractors did not have access to records 
at other facilities or to scanned documents (such as pathol-
ogy reports from non-VHA facilities) (n = 1287). Though 
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patients who were excluded tended to be older (mean 71 
years versus 68 years) and less likely to have small-cell lung 
cancer (SCLC) (6 % versus 13% non–small-cell lung can-
cer [NSCLC]), no statistically significant differences were 
observed in terms of sex, race, marital status, or stage of 
disease. Other exclusion criteria were: diagnosis at autopsy, 
death or enrollment in hospice on the 30th day or within 30 
days after diagnosis (n = 947); pre-existing or concurrent 
diagnosis of metastatic neoplasm other than lung cancer 
(n = 540); documentation of comfort measures only on the 
30th day or within 30 days after diagnosis (n = 91); enroll-
ment in a clinical trial, as trial care received might not have 
been documented in the VHA record (n = 59); or documen-
tation of life expectancy being 6 months or lesser at time of 
diagnosis in the patient’s problem list (n = 29).
Data Collection
As with all national VHA quality initiatives, the VHA 
External Peer Review Program process was used for chart 
review and performed under contract with West Virginia 
Medical Institute (Charleston, WV). Data were abstracted 
remotely from electronic health records by abstractors 
trained specifically for this study. Information pertaining 
to quality measures was obtained with follow-up through 
2009. Quality indicator results at the patient level were 
provided for each facility to review; staff members were 
given the opportunity to identify information missed in the 
initial abstraction, and data were updated by abstractors if 
appropriate.
Patient Characteristics
Age, sex, race/ethnicity, marital status, and tumor stage 
were provided by the Veterans Affairs Central Cancer Registry; 
if stage was not available, it was determined by chart abstrac-
tion. Rural-Urban Commuting Area codes (Version 2.0) were 
used to designate urban or rural residence.
Facility Characteristics
Facility-level characteristics were linked to medical 
centers through a VHA Healthcare Analysis and Information 
Group survey, in which information was provided on spe-
cific oncology-related services available at each center in 
2005 and in 2009. Queries included American College of 
Surgeons (ACOS) certification, presence of a tumor board, 
on-site lung biopsy capability, on-site cytopathology ser-
vices, presence of thoracic surgery services, on-site chemo-
therapy services, patient tracking by a nurse practitioner/
physician assistant, presence of inpatient palliative care 
consultation services, presence of an inpatient palliative 
care unit, and presence of outpatient palliative care consul-
tation services. The VHA assignation for facility complex-
ity level (low, medium, high) is based on patient population 
served, clinical services offered (e.g., acute, ambulatory), 
education or research involvement (e.g., teaching hospital 
affiliation), and administrative structure.10 Likewise, geo-
graphic region was based on VHA designation of facility 
location within the western, midwestern, northeastern, and 
southern United States.
Measure Development
Existing quality indicators and guidelines available in 
2008 pertaining to management of NSCLC and SCLC were 
identified by systematic literature review. Expert panels con-
vened to evaluate quality measure validity and feasibility 
through a modified Delphi approach outlined by the UCLA/
RAND Appropriateness Method.9 Measures were refined 
after structured discussion and panels asked to re-evaluate 
candidate indicators on their validity, potential for achiev-
ing improvement, and unintended consequences. The result-
ing set of quality indicators were then grouped into domains 
of Diagnosis and Staging, Treatment, Supportive Care, and 
 End-of-Life Care (Table 1).
Dependent Variables
The main outcome variable was adherence to the indi-
vidual quality indicators. Adherence was defined as receiving 
recommended therapy, refusing it, or having documented clin-
ical reasons against it. Adherence was scored dichotomously 
(fulfilled versus not fulfilled). Results for each indicator were 
expressed as a proportion, with number of eligible patients 
in the denominator and number of adherent patients in the 
numerator.
Statistical Analyses
To describe variation in adherence across VHA facili-
ties, the proportion adherent to each indicator overall and 
at the level of the individual facility was reported, with bar 
graphs to visually display results across facilities.
To identify facility characteristics associated with 
adherence to indicators stratified by domain, a two-level gen-
eral estimating equation was used to allow for open correla-
tion structure and account for clustering of patients within 
facilities. In multivariable models, potential predictors of 
adherence included all patient and facility characteristics 
significantly associated with adherence in bivariate analy-
ses, as well as those with perceived clinical and conceptual 
relevance (e.g., thoracic surgery service for the Treatment 
domain, palliative care consultation services for the End-
of-Life Care domain). Odds ratios represented the odds of 
fulfilling indicator criteria within the care domain relative to 
the reference group, with odds ratios greater than 1.0 indi-
cating increased odds of adherence. Separate models were 
constructed for each care domain, with patients stratified by 
disease stage (stage I–III, stage IV/unknown). All models 
controlled for patient age, sex, race/ethnicity, and marital 
status. All analyses were performed using SAS statistical 
software, version 9.1 (Cary, NC).
RESULTS
Patients
The sample included 4804 lung cancer patients who 
received care at 131 different VHA facilities. The predomi-
nantly white, male, elderly population had a mean age of 67.7 
years (SD 9.4 years). Almost half of these patients were mar-
ried, and the vast majority lived in an urban residence. Those 
with SCLC comprised 13% of the sample (Table 2).
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Facilities
More than 40% of the facilities were located in the 
south, accounting for care of 46% of patients (Tables 2 and 3). 
Although only 64% of facilities were categorized as low com-
plexity, 80% of patients were cared for in these facilities; 9% 
of facilities qualified as high complexity, providing care for 
3% of patients.
More than half of the facilities were ACOS-certified, 
whereas nearly all facilities had a tumor board and services 
for lung nodule biopsy, chemotherapy, and inpatient palliative 
care consultation. Approximately three quarters had a thoracic 
surgery service available on-site, whereas only one third had 
radiotherapy services and 17% had patient tracking support (by 
nurse practitioner or physician assistant). Psychosocial sup-
port with a psychiatric nurse practitioner or  advanced-practice 
registered nurse was available in 86% of facilities.
Performance
The number of cases eligible for indicators varied sub-
stantially across facilities (Table 1). Although all facilities con-
tributed cases to some quality indicators, for each indicator 
there was at least one facility with no eligible cases. Quality 
indicator adherence ranged from 23% to 89% for diagnosis and 
staging indicators, from 80% to 100% for treatment indicators, 
from 60% to 92% for supportive care indicators, and from 73% 
to 87% for end-of-life care indicators (Table 1). Variation in 
performance across facilities was substantial, even for quality 
indicators with high overall performance (Fig. 1).
Although the overall national rate for pathologic stag-
ing of the mediastinum for stage I, II, or III NSCLC was 93% 
and the mean score for facilities was 90%, close to one fifth 
of facilities with at least six eligible cases had adherence rates 
as low as 40% to 80%. Similarly, despite 99% of eligible 
patients nationwide receiving surgical resection for stages I to 
II NSCLC (when accounting for refusals of and contraindica-
tions to treatment), at least 10% of the facilities had rates of 
65% to 90%.11a Among indicators with lower overall perfor-
mance, less than half the facilities achieved 100% adherence 
to prevention of chemotherapy-related nausea/vomiting with 
a two-drug regimen, with the lowest adherence being 10% for 
one facility; no facility achieved 100% adherence for referral 
to palliative care or hospice at the end-of-life before death. 
Variation was particularly high for several other indicators, 
including mediastinoscopy for stage I to III NSCLC and out-
patient screening for pain.
Excellent facility performance in one domain of care 
was not associated with good performance in all domains of 
care. No single facility performed consistently well across all 
domains of care, and less than 1% performed in the lowest 
quartile on all domains (Fig. 2). Nine percent of the facilities 
TABLE 1.  Quality Indicators and Aggregate National Facility Performance Rates
Quality Indicators
Eligible  
Cases (n)
Cases Per  
Facility  
(Range)
VHA 
Adherence 
Rates  
(All Facilities)
Domain 1: Diagnosis and staging
  Stage (TNM or AJCC) recorded before treatment for NSCLC
  Pathologic staging of mediastinum in stage I, II, or III NSCLC
  Lymph node sampling of at least three stations during mediastinoscopy for stage I, II, or III NSCLC
  Lymph node sampling of at least three stations during surgical resection for stage I, II, or III NSCLC
4369
2605
175
1158
0 – 126
0 – 82
0 – 16
0 – 37
89%
93%
29%
44%
Domain 2: Cancer-directed treatment
  Resection for stage I or II NSCLC
  No adjuvant chemotherapy for stage IA NSCLC
  No radiation therapy for resected stage I or II NSCLC
  Adjuvant chemotherapy for resected stage II or IIIA NSCLC
  Combined chemotherapy and radiation for stage III NSCLC
  Platinum-based doublet chemotherapy for stage IV NSCLC
  Platinum-based doublet chemotherapy for SCLC
1575
435
973
279
922
891
444
0 – 48
0 – 16
0 – 35
0 – 14
0 – 34
0 – 23
0 – 19
99%
99%
100%
80%
88%
96%
97%
Domain 3: Supportive care
  Prevention of chemotherapy-related nausea/vomiting with two-drug regimen
  Outpatient screening for pain in advanced cancer using quantitative scale
  Reassessment after change in opioid treatment in advanced cancer
  Short-acting opioids for breakthrough pain in advanced cancer
  Radiation therapy for brain metastases
  Steroids within 24 hours of suspected spinal cord compression
  Spine MRI or myelography within 24 hours of suspected spinal cord compression
  Radiation or surgery within 24 hours for radiographically confirmed spinal cord compression
2029
1707 (9485 visits)
113
113
372
34
50
20
0 – 58
0 – 586 visits
0 – 9
0 – 9
0 – 14
0 – 3
0 – 4
0 – 2
88%
70% of visits
92%
92%
89%
74%
60%
90%
Domain 4: End-of-life care
  Outpatient screening for pain before death or hospice using quantitative scale
  Reassessment after change in opioid treatment before death or hospice
  Short-acting opioids for breakthrough pain before death or hospice
  Referral for palliative care or hospice before death
737 (1704 visits)
62
62
1787
0 – 69 visits
0 – 4
0 – 4
0 – 52
73% of visits
87%
79%
76%
Quality indicators, in their respective domains of care, with number of eligible patient cases and aggregate national rates of performance.
NSCLC, non–small cell lung cancer, SCLC, small-cell lung cancer; MRI, magnetic resonance imaging.
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were in the highest quartile for at least one domain of care, 
more than 30% for two domains, and 65% for three domains.
Facility-Level Predictors of Performance
Adjusting for patient characteristics, on-site lung biopsy 
was associated with a 35% increase in odds of adherence to 
domain 1 indicators (Diagnosis and Staging). ACOS certi-
fication was not associated with higher quality care in any 
domain, and facilities with ACOS certification showed a 14% 
decrease in odds of adherence to the quality indicators per-
taining to Diagnosis and Staging (Table 4). No facility-level 
characteristics were associated with adherence to domain 2 
indicators (Cancer-Directed Treatment), possibly because 
performance across all indicators was high (≥80%) (Table 5). 
No  facility-level characteristics were associated with higher 
performance on quality indicators in the Supportive Care 
domain; however, there was a decreased odds of adherence to 
supportive care measures affecting patients with stage I to III 
but not stage IV cancer in facilities with patient tracking by a 
nurse practitioner or physician assistant (domain 3) (Table 6). 
Because many of the supportive care measures impact patients 
with advanced cancer only, the aspect of supportive care that 
was assessed in early-stage patients was prophylaxis of nausea 
and vomiting. For End-of-Life Care (domain 4), diagnosis and 
treatment within the same facility, availability of cancer psy-
chiatry/psychology consultation services, and availability of 
mature (i.e., present since 2005) inpatient as well as outpatient 
palliative care consultation services were all associated with 
better adherence.
DISCUSSION
In this retrospective observational study of veterans 
with lung cancer, we found that adherence to quality mea-
sures was high; however, substantial variation in perfor-
mance on quality indicators was observed across facilities, 
and room for improvement was noted in some measures. 
In addition, facilities that performed well in one domain of 
lung cancer care did not necessarily perform better in other 
domains. Furthermore, no organizational characteristics 
were consistently associated with higher performance on 
quality indicators.
The majority of facilities reported having tumor boards 
and services (e.g., lung nodule biopsy, chemotherapy, tho-
racic surgery, inpatient palliative care) that might intuitively 
be predictive of quality indicator fulfillment. ACOS certifi-
cation was present in a little over half of surveyed facilities, 
whereas one third of facilities had on-site radiotherapy avail-
able. Few of these factors, however, seemed to be associated 
with adherence to lung cancer quality indicators; indeed, no 
TABLE 2.  Patient Characteristics (N = 4804)
Age (yrs)
  <55
  55–64
  65–79
  80+
342 (7%)
1750 (36%)
2213 (47%)
499 (10%)
Male 4704 (98%)
Race/ethnicity
  White
  Black
  Other (Hispanic, Asian, Other, or unknown)
3956 (83%)
741 (15%)
107 (2%)
Residence
  Urban
  Rural
3369 (70%)
1435 (30%)
Married/living with partner 2284 (48%)
Lung cancer type
  Non–small cell lung cancer
  Small-cell lung cancer 
4167 (87%)
637 (13%)
Stage
  I
  II
  III
  IV
  Unknown
778 (16%)
688 (14%)
1055 (22%)
2009 (42%)
274 (6%)
Geographic region
  West
  Midwest
  Northeast
  South
885 (18%)
1060 (22%)
671 (14%)
2188 (46%)
Complexity level of treatment facility
  Low
  Moderate
  High
3832 (80%)
822 (17%)
150 (3%)
Mean number of facilities involved in diagnosis and 
treatment
1.63 (SD 0.58)
Descriptive stastistics are shown for patient sociodemographic and tumor 
characteristics, as well as characteristics of the facility associated with the patient.
TABLE 3.  Organizational Characteristics and Availability of 
Oncology Services
Facilities  
(N = 131)
Geographic region
  West
  Midwest
  Northeast
  South
22 (22%)
19 (19%)
17 (17%)
41 (42%)
Complexity level
  Low
  Moderate
  High
63 (64%)
27 (27%)
9 (9%)
ACOS certification 58 (59%)
Tumor board present 91 (92%)
Services available on-site
  Lung nodule biopsy
  Cytopathology
  Thoracic surgery
  Chemotherapy
  Radiotherapy
  Patient tracking (by NP or PA)
95 (96%)
86 (87%)
76 (77%)
96 (97%)
33 (33%)
17 (17%)
Palliative care services
  Inpatient palliative care consultation
  Inpatient palliative care unit
  Outpatient palliative care consultation
92 (93%)
71 (72%)
77 (78%)
Psychosocial support
 Psychiatric NP or advanced-practice RN 86 (87%)
Descriptive statistics of facility-level characteristics are shown, including services 
specific to oncology.
ACOS, American College of Surgeons; NP, nurse practitioner; PA, physician 
assistant; RN, registered nurse.
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significant factors among those studied were found to influ-
ence adherence among the treatment-related measures. The 
only factors that were associated with improved quality were 
(1) on-site lung biopsy for the Diagnosis and Staging domain, 
and (2) diagnosis and treatment in the same facility, cancer 
psychiatry/psychology services, and inpatient as well as out-
patient palliative care services available since 2005 for the 
 End-of-Life Care domain.
There was also substantial variation across facilities 
even in domains (such as Treatment) for which performance 
was 80% to 100%; this was not explained by facilities with 
small numbers of eligible cases acting as outliers. In addition, 
no facility performed well on every measure or even every 
domain. This suggests that a facility’s characteristics may 
positively impact care in one area along the care continuum, 
such as seen with the positive association of palliative care 
services with improved facility scores in End-of-Life Care, 
but may not help or may even hinder care in another area, such 
as Diagnosis and Staging.
Variations in care based on nonclinical factors have 
been observed for at least several decades, with Wennberg 
and Gittelsohn11 in 1973 providing a seminal report of vast 
differences in health services for the same condition, based 
on municipality within the state of Vermont. Since then, mul-
tiple studies have demonstrated marked heterogeneity in care 
despite the presence of consensus-driven,  evidence-based 
guidelines for almost every disease process. Although 
 provider-level variation is an important cause, with varying 
practices seen at this level, differences by hospital or facil-
ity also have been noted. With regard to cancer care, hospital 
volume,12 hospital cachement population and racial compo-
sition,13 and oncologic treatment availability (chemotherapy 
or radiotherapy),14,15 among others, have been associated with 
quality of care.
FIGURE 1.  Distribution of mean scores by facility for selected indicators. Mean scores of each facility (with at least 5 or 
more eligible cases) for selected quality indicators in the four care domains are represented by each bar. The green line indi-
cates the mean score across facilities, whereas the blue line indicates the median score across facilities for the indicator.  
A wide range of mean scores across facilities was seen, though performance rates overall were generally high. NSCLC,  
non–small cell lung cancer.
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FIGURE 2.  Performance across domains: percentage of facili-
ties with domain quality scores in the highest and lowest quar-
tiles. The proportion of facilities with performance scores in the 
highest quartile and lowest quartile in zero, one, two, three, 
or four of the four possible care domains is depicted. Although 
high performance was not consistent across all domains for 
any given facility, 35% of facilities did not perform in the low-
est quartile on any domain and very few facilities performed 
poorly in all domains.
TABLE 4.   Facility-Level Adjusted Odds of Indicator Adherence
Stage I–III Stage IV
OR 95% CI OR 95% CI
Diagnosis and staging
  Facility complexity level
   Low
   Medium
1.00
0.80
0.49–1.28
   High 0.67 0.33–1.36
  Geographic region
   West
   Midwest
1.00
1.12 0.98–1.29
   Northeast 1.16 0.97–1.40
   South 1.18 1.04–1.34
  ACOS certification 0.86 0.77–0.97
  Tumor board 1.02 0.72–1.45
  On-site lung biopsy 1.35 1.11–1.64
  On-site cytopathology 0.98 0.84–1.13
  Diagnosis & treatment in same facility 0.85 0.69–1.05
Treatment
  Facility complexity level
   Low
   Medium
1.00
0.96 0.66–1.39
1.00
2.09 0.91–4.82
   High 1.07 0.63–1.80 2.15 0.71–6.50
  Geographic region 
   West
   Midwest
1.00
1.07 0.94–1.22
1.00
1.27 0.94–1.72
   Northeast 1.01 0.90–1.13 1.14 0.84–1.53
   South 0.98 0.87–1.11 1.20 0.93–1.55
  ACOS certification 0.94 0.86–1.03 0.98 0.80–1.20
  Tumor board 1.28 0.97–1.70 0.49 0.29–1.20
  Thoracic surgery service 0.85 0.66–1.10 1.03 0.73–1.45
  On-site chemotherapy services 0.59 0.16–2.18 0.58 0.32–1.03
Supportive care
  Facility complexity level
(Continued)
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Within an integrated health care system that spans the 
entire nation geographically, variations at the hospital level 
are of particular interest. As the burden of cancer and its 
care continually increases within the VHA,16,17 identifying 
organizational determinants of care introduces the unique 
opportunity for global management of cancer services and the 
implementation of facility-level interventions that improve 
quality of care in a centralized, effective, and potentially 
   Low
   Medium
1.00
1.39 0.95–2.03
1.00
1.18 0.62–2.26
   High 1.27 0.69–2.34 0.90 0.39–2.07
  Geographic region
   West
   Midwest
1.00
0.96 0.74–1.25
1.00
0.90 0.72–1.13
   Northeast 0.88 0.68–1.14 0.92 0.76–1.12
   South 1.08 0.83–1.42 1.05 0.87–1.26
  Patient tracking by NP or PA 0.73 0.60–0.90 0.93 0.80–1.07
  Inpatient palliative care service
   Available in 2005 1.16 0.59–2.26 1.03 0.65–1.62
   Available after 2005 1.90 0.69–5.24 1.19 0.63–2.26
  Inpatient palliative care unit/hospice
   Available in 2005 1.19 0.70–2.00 1.00 0.60–1.66
   Available after 2005 1.23 0.54–2.79 0.84 0.37–1.91
  Outpatient palliative care service
   Available in 2005 1.00 0.66–1.51 0.95 0.68–1.31
   Available after 2005 0.71 0.37–1.36 0.78 0.45–1.36
End-of-life care
  Facility complexity level
   Low
   Medium
1.00
0.65 0.27–1.55
   High 0.72 0.37–1.41
  Geographic region
   West
   Midwest
1.00
1.06 0.90–1.25
   Northeast 1.07 0.89–1.28
   South 1.17 0.98–1.41
  Diagnosis and treatment in same facility 2.75 1.89–4.01
  Patient tracking by NP or PA 0.90 0.80–1.01
  Cancer psychiatry/psychology service 1.32 1.15–1.53
  Inpatient palliative care service
   Available in 2005 1.57 1.02–2.41
   Available after 2005 1.88 0.92–3.83
  Inpatient palliative care unit/hospice
   Available in 2005 1.13 0.87–1.48
   Available after 2005 1.27 0.73–2.21
  Outpatient palliative care service
   Available in 2005 1.45 1.11–1.90
   Available after 2005 1.27 0.73–2.21
Facility-level adjusted rates of adherence to indicators aggregated within care domain are shown. Few organizational characteristics were associated with better adherence at the 
facility level.
OR, odds ratio; CI, confidence interval; ACOS, American College of Surgeons; NP, nurse practitioner; PA, physician assistant.
All models adjusted for patient age, sex, race/ethnicity, marital status, and urban (vs. rural) residence.
All models adjusted for presence of facility of palliative care services.
Domain 2: Also adjusted for interaction between consultation services and facility complexity level.
Domains 3 and 4: Also adjusted for interaction between consultation services and facility complexity level, inpatient palliative care unit, and facility complexity level.
Odds ratios in bold indicate those variables with statistically significant increased/decreased odds of adherence compared to reference group.
TABLE 4.  (Continued)
Stage I–III Stage IV
OR 95% CI OR 95% CI
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more cost-effective manner.8,18 Indeed many of the pioneer-
ing programs to evaluate quality of care for hospitals and 
cancer programs, including efforts by The Joint Commission 
and the ACOS Commission on Cancer, are based on primar-
ily structural determinants of quality.2,19–21 With the important 
(and intuitive) exceptions of on-site lung biopsy, palliative 
care, counseling services, and diagnosis and treatment within 
the same facility, we did not identify any organizational char-
acteristics or resources that predicted better performance on 
process quality indicators for lung cancer care, which would 
aid in recommendations for changes to improve the care at 
facilities with lower performance.
The lack of a coherent picture regarding organizational 
influences attests to the challenges facing quality measure-
ment and, ultimately, quality-improvement efforts. Although 
studies have identified organizational factors associated with 
better performance or improvement on individual quality indi-
cators,21–24 the relationship between structural characteristics 
of the health care delivery system and overall quality of care 
remains elusive. These studies are typically limited by having 
only more abstract or telescopic data regarding the organiza-
tional structure of hospitals or facilities, such as ownership or 
academic affiliation. We were able to make use of a unique 
survey that included more comprehensive information regard-
ing the resources and organization of cancer care in facili-
ties; yet, even with this level of detail, we were not able to 
discern any organizational factors that were associated with 
higher quality of care. This is consistent with findings from 
a data-mining study in which one center’s characteristics and 
organizational structure could not predict the performance of 
another in a VHA Quality Improvement Collaborative.1
In this regard, the integrated structure of the VHA—
with support systems that tie low- to high-complexity facili-
ties and with potential for centralized implementation of 
care standards—may possibly circumvent the variability 
seen in other health care systems. Despite the burden on 
 low-complexity hospitals, where 80% of the study sample 
received care, high levels of quality were achieved and no 
association was observed with facility complexity. This runs 
counter to general observations outside the VHA of increas-
ing quality among institutions offering acute, higher-volume, 
tertiary or quarternary care, particularly in the United States. 
The VHA results are more in keeping with what is seen among 
nationalized systems in other industrialized countries, where 
variability in quality is diminished despite complexity level 
and may be considered an advantage to such organization.25–28
Several limitations must be considered when applying 
the results of this study to other settings. As an integrated health 
care system, the VHA represents a structural configuration that 
may positively or negatively impact care in a manner not readily 
generalizable to most American health care settings. However, 
as new models of care are developed, such as Accountable Care 
Organizations,29 findings from the VHA may prove more relevant 
and applicable to other health care groups. In addition to provid-
ing a somewhat singular health care environment, the VHA’s 
long-standing experience with electronic health records is also 
exceptional, if not unique. Arguably, electronic records facilitate 
large-scale quality measurement that is more difficult to achieve 
in other settings, making comparisons and generalizations with 
other health care systems less tenable. With recent incentives 
and mandates for electronic record-keeping, however, the VHA 
may provide a model for quality assessment and improvement, 
whose practices may become more pertinent for other systems. 
As always, there is inherent error involved in the collection and 
use of both abstracted clinical and hospital survey data, and the 
cross-sectional nature of both performance and facility informa-
tion allow only for associations rather than causal relationships. 
Finally, although the survey of oncologic services was quite 
detailed, other, unmeasured variables of structure may have been 
more influential determinants of quality.
In summary, this study is encouraging in demonstrating 
that quality of lung cancer care can be measured on a large 
scale and that, in general, adherence with quality measures 
is high within the VHA. Although no one facility performed 
well across all measures or domains and substantial variation 
between facilities was observed, the range in performance 
indicates that high quality of care may be attained. The dif-
ficulty in identifying consistent predictors of performance at 
the facility level suggests that efforts to improve quality will 
need to consider many unique factors in how care is delivered 
at individual facilities as well as the human dynamics of care 
delivery and, ultimately, the organizational culture and pro-
cesses that enable quality improvement. Further research is 
required to elucidate how these complex relationships relate to 
quality of care and impact efforts to improve care.
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